We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01667718
Recruitment Status : Completed
First Posted : August 17, 2012
Last Update Posted : December 13, 2012
Sponsor:
Information provided by (Responsible Party):
Dr. HONG LU, Shanghai Jiao Tong University School of Medicine

Brief Summary:
To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and without Bismuth for H.pylori treatment.

Condition or disease Intervention/treatment Phase
Functional Dyspepsia Peptic Ulcer Drug: Bismuth Drug: Lansoprazole Drug: Levofloxacin Drug: Amoxicillin Phase 4

Detailed Description:
The success rate of the standard triple therapy for H. pylori infection is decreasing recently.Fluoroquinolone has been proposed to replace clarithromycin as an alternative in the treatment. However prevalence of H.pylori resistance to Levofloxacin has increased rapidly in our area. The purpose of this study is to observe the efficacy of 14 day Levofloxacin triple therapy-based, bismuth-containing quadruple therapy for H.pylori treatment.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 161 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Levofloxacin-containing Therapy for Helicobacter Pylori Treatment
Study Start Date : May 2012
Primary Completion Date : October 2012
Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Levofloxacin-triple therapy
Lansoprazole (Proton Pump Inhibitor), Levofloxacin, Amoxicillin
Drug: Lansoprazole
Lansoprazole 30 mg b.i.d.for 2 weeks
Other Name: Proton Pump Inhibitor
Drug: Levofloxacin
Levofloxacin 0.5 q.d. for 2 weeks
Drug: Amoxicillin
Amoxicillin 1 g b.i.d. for 2 weeks
Experimental: Levofloxacin-quadruple therapy
Lansoprazole (Proton Pump Inhibitor),Bismuth, Levofloxacin, Amoxicillin
Drug: Bismuth
Bismuth 220mg b.i.d for 2 weeks
Other Name: Bismuth potassium citrate
Drug: Lansoprazole
Lansoprazole 30 mg b.i.d.for 2 weeks
Other Name: Proton Pump Inhibitor
Drug: Levofloxacin
Levofloxacin 0.5 q.d. for 2 weeks
Drug: Amoxicillin
Amoxicillin 1 g b.i.d. for 2 weeks



Primary Outcome Measures :
  1. eradication rate of Helicobacter pylori [ Time Frame: 2 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients who presented with upper gastrointestinal symptoms and endoscopically proven H.pylori-positive functional dyspepsia and scarred peptic ulcer

Exclusion Criteria:

  • patients with peptic ulcer, previous H.pylori eradication therapy, previous gastric surgery, pregnancy, lactation, major systemic diseases, receipt of anti-secretory therapy, antibiotics or bismuth in the preceding 4 weeks, or allergy to any one of the medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01667718


Locations
China, Shanghai
Shanghai Jiao-Tong University School of Medicine Renji Hospital
Shanghai, Shanghai, China, 200127
Sponsors and Collaborators
Shanghai Jiao Tong University School of Medicine
Investigators
Principal Investigator: Hong Lu Shanghai Jiao-Tong University School of Medicine Renji Hospital

Responsible Party: Dr. HONG LU, Professor of GI Division, Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier: NCT01667718     History of Changes
Other Study ID Numbers: rjkls2012011
First Posted: August 17, 2012    Key Record Dates
Last Update Posted: December 13, 2012
Last Verified: December 2012

Keywords provided by Dr. HONG LU, Shanghai Jiao Tong University School of Medicine:
eradication
helicobacter pylori
bismuth

Additional relevant MeSH terms:
Dyspepsia
Peptic Ulcer
Signs and Symptoms, Digestive
Signs and Symptoms
Duodenal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Amoxicillin
Levofloxacin
Ofloxacin
Lansoprazole
Dexlansoprazole
Proton Pump Inhibitors
Bismuth
Potassium Citrate
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Infective Agents, Urinary
Renal Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents